Prognostic Values of LAPTM4B-35 in Human Cancer: A Meta-analysis.

: Lysosome-associated protein transmembrane-4β-35(LAPTM4B-35) has been observed overexpressed in multiple malignant tumors. However, the prognostic value of LAPTM4B-35 remains controversial. Therefore, we conducted a meta-analysis to evaluate the prognostic value of LAPTM4B-35 in human cancers. The relevant publications were obtained by systematically searching the PubMed, Web of Science, Embase, Wanfang, and China National Knowledge Infrastructure (CNKI) databases. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated for the prognosis value of LAPTM4B-35 for cancer patient. Our result suggest that LAPTM4B-35 overexpression is significantly associated with poor overall survival (OS) (HR = 2.49, 95% CI = 1.87-3.32, < 0.001), disease-free survival (DFS) (HR = 2.43, 95% CI = 1.35-4.35, = 0.003), and progression-free survival (PFS) (HR = 4.12, 95% CI = 2.30-7.37, < 0.001). Moreover, subgroup analysis revealed significant association with poor OS in lung (HR = 2.05, 95% CI = 1.37-3.06, < 0.001), gastric carcinoma (HR = 1.88, 95% CI = 1.01-3.50, < 0.047) and ovarian cancer (HR = 4.94, 95% CI = 1.44-16.94, = 0.011). : LAPTM4B-35 may be a novel predictive biomarker and a potential target for treatment.